4574.T

The company maintains a strong liquidity position, with cash and equivalents amounting to ¥4.26 billion, representing 34.7% of total assets. Its liquidity FPT score indicates a low risk of liquidity stress, supported by a current ratio of 3.36 and a debt-to-equity ratio of 0.1, suggesting a conservative capital structure. Free cash flow of ¥885 million and operating cash flow of ¥815 million further reinforce its ability to service obligations and fund operations without external financing.

Profitability metrics show a return on equity (ROE) of 10.85% and a return on assets (ROA) of 7.53%, both exceeding the industry median for Pharmaceuticals, which typically ranges between 8% and 10% for ROE and 5% to 7% for ROA. Gross profit of ¥3.48 billion and operating income of ¥452 million indicate a healthy margin structure, though net income of ¥924 million suggests some pressure from non-operating expenses or taxes.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in the Japanese domestic market. No material revenue concentration by customer or product line is disclosed, but the absence of segment reporting limits visibility into growth drivers.

Growth trajectory appears stable, with revenue of ¥6.4 billion in the latest period. Analysts estimate revenue of ¥6.75 billion for the next period, implying a 4.0% year-over-year growth. Earnings per share (EPS) estimates of ¥12.94 suggest a 25.0% decline from the actual ¥18.37 in the last reported period, indicating potential near-term earnings pressure. The company's price-to-earnings ratio of 13.92 is in line with the industry median, suggesting a fairly valued stock.

Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash position reduce financial leverage risk. However, the absence of disclosed capital expenditure plans or R&D investment details limits visibility into long-term growth potential. No dilution risk is currently flagged, with shares outstanding remaining unchanged between basic and diluted counts.

Recent events include the latest financial filing, which shows consistent revenue and margin performance. No material changes in business strategy, regulatory actions, or major product launches are disclosed in the latest available data. Analysts have not issued significant revisions to earnings or revenue estimates, suggesting stable expectations.